KRAS and pancreatic adenocarcinoma: This study reports on a dendritic cell-based vaccine against KRAS peptides in PAAD patients and describes the functional characteristics of four KRAS G12V-specific TCRs restricted to the HLA-A3 superfamily of class I alleles with potential for development of adoptive T cell therapies.